Houston-based Moleculin Biotech, Inc., currently trading at $0.80 and showing a market capitalization of $2.4 million, has entered into an agreement with an investor to modify certain terms of ...

Aardvark’s lead candidate ARD-101 is being investigated in a Phase III study for hyperphagia in Prader-Willi syndrome.

Bhopal: Chief minister Mohan Yadav said on Friday that Madhya Pradesh is emerging as a global hub for industrial investment and strategic innovation.

Biotech stocks are revolutionizing healthcare with breakthrough innovations, leading the charge in precision therapies and ...

Financial writer advises caution on Jyong Biotech Ltd. IPO due to high debt, legal issues, and FDA challenges. Click for my ...

EVENTS DURING THE FOURTH QUARTEREuropean Patent Office granted Active Biotech's patent application for eye drop formulation of laquinimod (October 23)Active Biotech's clinical trial of tasquinimod in ...

M&A in biotech and pharma is expected to surge in late 2024 as regulatory uncertainties ease. Discover trends, key players, and areas of high interest.

So, here we are, launching our fourth edition of Fierce Biotech's layoff tracker. As always, if you know of a layoff occurring at a biotech, please reach out to the Fierce Biotech editorial team ...

A new year means a new Fierce Biotech Fundraising Tracker to record the significant amounts of venture capital being funneled into the industry. We're maintaining the criteria we used for last ...

Plastic is the most prevalent marine pollutant, and plastic surfaces are the fastest growing habitat in the ocean. Researchers at the University of Hawai'i (UH) at Mānoa have recently discovered ...

Biotech stocks are in the eye of the storm as the world recovers from the global pandemic. Government institutions and professional traders are banking on biotech stocks to continually develop a ...

Looking for the best biotech penny stocks? The most important innovation of the 1990s was the internet — today, it would be a vaccine for COVID-19. If these times have anything to say about it ...